

# Kouros Owzar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3995041/publications.pdf>

Version: 2024-02-01

73  
papers

1,625  
citations

331670

21  
h-index

330143

37  
g-index

76  
all docs

76  
docs citations

76  
times ranked

4208  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. <i>International Journal of Cancer</i> , 2022, 150, 279-289.	5.1	8
2	Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. <i>British Journal of Cancer</i> , 2022, 126, 265-274.	6.4	8
3	Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 513-523.	3.9	2
4	DNA-Damage-Induced Alternative Splicing of p53. <i>Cancers</i> , 2021, 13, 251.	3.7	10
5	RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry. <i>Lung Cancer</i> , 2021, 153, 90-98.	2.0	6
6	Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). <i>Oncologist</i> , 2021, 26, 560-e1103.	3.7	6
7	Whole-Exome Sequencing of Radiation-Induced Thymic Lymphoma in Mouse Models Identifies Notch1 Activation as a Driver of p53 Wild-Type Lymphoma. <i>Cancer Research</i> , 2021, 81, 3777-3790.	0.9	10
8	An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9521-9521.	1.6	0
9	Comparative analysis of RNA enrichment methods for preparation of <i>Cryptococcus neoformans</i> RNA sequencing libraries. <i>G3: Genes, Genomes, Genetics</i> , 2021, 11, .	1.8	6
10	Obesity and altered angiogenic-related gene expression in endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 163, 320-326.	1.4	5
11	Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence. <i>Nature Communications</i> , 2020, 11, 5017.	12.8	28
12	Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. <i>Nature Communications</i> , 2020, 11, 6410.	12.8	66
13	Plasmonic nanobiosensors for detection of microRNA cancer biomarkers in clinical samples. <i>Analyst</i> , 2020, 145, 4587-4594.	3.5	24
14	The Long Noncoding RNA <i>NEAT1</i> Promotes Sarcoma Metastasis by Regulating RNA Splicing Pathways. <i>Molecular Cancer Research</i> , 2020, 18, 1534-1544.	3.4	16
15	Differential expression of immune related genes in high-grade ovarian serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 662-668.	1.4	3
16	Predictive accuracy of markers or risk scores for interval censored survival data. <i>Statistics in Medicine</i> , 2020, 39, 2437-2446.	1.6	3
17	fastJT: An R package for robust and efficient feature selection for machine learning and genome-wide association studies. <i>BMC Bioinformatics</i> , 2019, 20, 333.	2.6	2
18	Late effects of total body irradiation on hematopoietic recovery and immune function in rhesus macaques. <i>PLoS ONE</i> , 2019, 14, e0210663.	2.5	20

#	ARTICLE	IF	CITATIONS
19	<scp>SET</scp> alpha and <scp>SET</scp> beta <scp>mRNA</scp> isoforms in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 605-615.	2.5	24
20	Mutational landscape in genetically engineered, carcinogen-induced, and radiation-induced mouse sarcoma. <i>JCI Insight</i> , 2019, 4, .	5.0	47
21	Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Cvhd. <i>Blood</i> , 2019, 134, 874-874.	1.4	4
22	Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.. <i>Journal of Clinical Oncology</i> , 2019, 37, 587-587.	1.6	0
23	Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 49-55.	1.5	26
24	Facilitating the Calculation of the Efficient Score Using Symbolic Computing. <i>American Statistician</i> , 2018, 72, 199-205.	1.6	0
25	Novel genetic variants in the P38MAPK pathway gene <i>ZAK</i> and susceptibility to lung cancer. <i>Molecular Carcinogenesis</i> , 2018, 57, 216-224.	2.7	9
26	Genetic variants in the plateletâ€derived growth factor subunit B gene associated with pancreatic cancer risk. <i>International Journal of Cancer</i> , 2018, 142, 1322-1331.	5.1	20
27	Genetic variation determines VEGF-A plasma levels in cancer patients. <i>Scientific Reports</i> , 2018, 8, 16332.	3.3	10
28	<tt>bcSeq</tt>: an R package for fast sequence mapping in high-throughput shRNA and CRISPR screens. <i>Bioinformatics</i> , 2018, 34, 3581-3583.	4.1	4
29	Post-Irradiation Treatment with a Superoxide Dismutase Mimic, MnTnHex-2-PyP5+, Mitigates Radiation Injury in the Lungs of Non-Human Primates after Whole-Thorax Exposure to Ionizing Radiation. <i>Antioxidants</i> , 2018, 7, 40.	5.1	30
30	The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. <i>PLoS ONE</i> , 2018, 13, e0202272.	2.5	13
31	The Association of FCGR2A and FCGR3A polymorphisms with outcomes in cetuximab treated metastatic colorectal cancer patients: CCTG and AGITG CO.20 trial analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-633.	1.6	0
32	Apoptotic capacity and risk of squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2017, 72, 166-176.	2.8	19
33	Pathwayâ€analysis of published genomeâ€wide association studies of lung cancer: A potential role for the <i>CYP4F3</i> locus. <i>Molecular Carcinogenesis</i> , 2017, 56, 1663-1672.	2.7	13
34	Reduced mRNA expression of nucleotide excision repair genes in lymphocytes and risk of squamous cell carcinoma of the head and neck. <i>Carcinogenesis</i> , 2017, 38, 504-510.	2.8	6
35	Functional variants in DCAF4 associated with lung cancer risk in European populations. <i>Carcinogenesis</i> , 2017, 38, 541-551.	2.8	16
36	Identification of a DNA Damageâ€Induced Alternative Splicing Pathway That Regulates p53 and Cellular Senescence Markers. <i>Cancer Discovery</i> , 2017, 7, 766-781.	9.4	70

#	ARTICLE	IF	CITATIONS
37	Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. <i>Scientific Reports</i> , 2017, 7, 44634.	3.3	10
38	An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. <i>Blood</i> , 2017, 130, 2131-2145.	1.4	37
39	SparkScore: Leveraging Apache Spark for Distributed Genomic Inference. , 2016, , .		6
40	Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). <i>Cancer Medicine</i> , 2016, 5, 2249-2260.	2.8	19
41	A Novel Genetic Variant in Long Non-coding RNA Gene NEXN-AS1 is Associated with Risk of Lung Cancer. <i>Scientific Reports</i> , 2016, 6, 34234.	3.3	48
42	Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3597-3597.	1.6	9
43	A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503.. <i>Journal of Clinical Oncology</i> , 2016, 34, 538-538.	1.6	0
44	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. <i>Journal of Clinical Oncology</i> , 2015, 33, 4167-4175.	1.6	149
45	Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). <i>Journal of the National Cancer Institute</i> , 2015, 107, djv188.	6.3	6
46	Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2015, 139, 23-29.	1.4	27
47	HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 3583-3583.	1.6	1
48	Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 927-938.	2.3	27
49	Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines. <i>Frontiers in Oncology</i> , 2014, 4, 163.	2.8	8
50	25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance). <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	28
51	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. <i>Nature Genetics</i> , 2014, 46, 994-1000.	21.4	294
52	Robust rat pulmonary radioprotection by a lipophilic Mn N-alkylpyridylporphyrin, MnTnHex-2-PyP5+. <i>Redox Biology</i> , 2014, 2, 400-410.	9.0	27
53	Next Generation Distributed Computing for Cancer Research. <i>Cancer Informatics</i> , 2014, 13s7, CIN.S16344.	1.9	7
54	Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10508-10508.	1.6	12

#	ARTICLE	IF	CITATIONS
55	Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE).. Journal of Clinical Oncology, 2014, 32, e16061-e16061.	1.6	0
56	A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).. Journal of Clinical Oncology, 2014, 32, 9612-9612.	1.6	0
57	MicroRNA Expression Differentiates Squamous Epithelium from Barrett's Esophagus and Esophageal Cancer. Digestive Diseases and Sciences, 2013, 58, 3178-3188.	2.3	30
58	Prognostic significance of differential expression of angiogenic genes in women with invasive high-grade serous ovarian carcinoma.. Journal of Clinical Oncology, 2013, 31, 5509-5509.	1.6	2
59	Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance).. Journal of Clinical Oncology, 2013, 31, 11011-11011.	1.6	0
60	Participation in cancer pharmacogenomic studies in 8,456 patients registered to Cancer and Leukemia Group B (Alliance) clinical trials.. Journal of Clinical Oncology, 2013, 31, 6501-6501.	1.6	0
61	A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance).. Journal of Clinical Oncology, 2013, 31, 11053-11053.	1.6	0
62	25-hydroxyvitamin D levels and survival in patients with advanced pancreatic cancer (APC): Findings from CALGB 80303.. Journal of Clinical Oncology, 2013, 31, 4022-4022.	1.6	0
63	A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303. Clinical Cancer Research, 2012, 18, 577-584.	7.0	91
64	Power and Sample Size Calculations for SNP Association Studies With Censored Time-to-Event Outcomes. Genetic Epidemiology, 2012, 36, 538-548.	1.3	30
65	A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502. Blood, 2012, 120, 230-230.	1.4	14
66	Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance). Blood, 2012, 120, 816-816.	1.4	3
67	Effect of age on the pharmacokinetics of busulfan (Bu): An alliance study.. Journal of Clinical Oncology, 2012, 30, 2533-2533.	1.6	0
68	Statistical Considerations for Analysis of Microarray Experiments. Clinical and Translational Science, 2011, 4, 466-477.	3.1	28
69	Comparison of two Mn porphyrin-based mimics of superoxide dismutase in pulmonary radioprotection. Free Radical Biology and Medicine, 2008, 44, 982-989.	2.9	111
70	Designing phase II studies in cancer with time-to-event endpoints. Clinical Trials, 2008, 5, 209-221.	1.6	14
71	A Copula Approach for Detecting Prognostic Genes Associated With Survival Outcome in Microarray Studies. Biometrics, 2007, 63, 1089-1098.	1.4	9
72	p-Value Calculation for Multistage Phase II Cancer Clinical Trials. Journal of Biopharmaceutical Statistics, 2006, 16, 765-775.	0.8	18

#	ARTICLE	IF	CITATIONS
73	A multiple testing procedure to associate gene expression levels with survival. <i>Statistics in Medicine</i> , 2005, 24, 3077-3088.	1.6	24